

BSE SENSEX
40,821

S&P CNX
12,038

CMP: INR1,488 TP: INR1,815 (+22%)

Buy



COLGATE-PALMOLIVE

Stock Info

	CLGT IN
Bloomberg	CLGT IN
Equity Shares (m)	272
M.Cap.(INRb)/(USDb)	404.8 / 5.7
52-Week Range (INR)	1641 / 1096
1, 6, 12 Rel. Per (%)	-7/26/9
12M Avg Val (INR M)	654
Free float (%)	49.0

Financials Snapshot (INR b)


Y/E March	2019	2020E	2021E
Sales	44.6	47.3	53.8
EBITDA	12.4	12.4	15.2
Adj. PAT	7.5	8.2	10.2
Adj. EPS (INR)	27.4	30.1	37.5
EPS Gr. (%)	8.8	9.9	24.5
BV/Sh.(INR)	53.2	50.8	46.5
RoE (%)	50.1	57.9	77.1
RoCE (%)	47.9	54.2	71.6
P/E (x)	54.3	49.4	39.7
P/BV (x)	28.0	29.3	32.0

Shareholding pattern (%)

As On	Sep-19	Jun-19	Sep-18
Promoter	51.0	51.0	51.0
DII	11.6	10.5	13.3
FII	15.5	15.1	13.3
Others	22.0	23.4	22.4

FII Includes depository receipts

Stock Performance (1-year)



Poised for strong earnings growth over medium term

Inexpensive valuations bolster upside potential

We recently met Colgate’s (CLGT) management to understand its strategy to drive growth amidst changing market dynamics. Key highlights:

- CLGT’s market share has been stable over the past few quarters.
- Volume growth and market share expansion have taken precedence as part of its new strategy, even if it is at the cost of near-term profitability.
- Direct reach has increased by 30% over the past year.
- Good Rabi crop may not necessarily translate into a significant boost for FMCG sector volumes. It may take rural growth at par with urban growth. Anything additional will be a bonus.
- Premiumization is back in focus. No material downtrading is happening either.
- No material capex required until Dec’22.
- In our [note](#) post the corporate tax cut, we had included Colgate (CLGT) among our top picks. In another [note](#) on CLGT earlier this month, we had examined past instances among Indian MNCs where management change heralded a significant change in the strategy for the better. We remain bullish on CLGT from the medium-term perspective, given its reasonable valuations (39.7x FY21E EPS – a huge discount to MNC peer multiples of 50x-56x), likely escalation in earnings momentum and sharp potential improvement in the already impressive RoCE. Targeting 45x Sep’21E, we maintain our target price of INR1,815 with a Buy rating.

Stable market share over past few quarters

- It was important for CLGT to arrest the hemorrhage in the toothpaste market share before resuming the growth path. In that regard, the company has done well over the past few quarters to maintain a stable market share of 51%-52% (although still below the peak of ~58%), led by:
 - **Launch of a host of herbal products** like Cibaca Ved Shakti and Swarna Ved Shakti, as well as the recently launched Charcoal toothpaste. This apart, it has a strong pipeline of products awaiting launch in both the herbal and non-herbal categories.
 - **Slowdown in growth of herbal** from ~30% YoY to mid-teens now. CLGT’s market share in herbal is around one third and therefore sharp growth in the salience of the category (now 25-30% of toothpaste market sales) impacted its overall market share.
 - **Direct distribution reach** which reportedly expanded by 30% over the past year. At a time when wholesale trade (both rural and urban) is facing pressure, this move would have helped arrest the hemorrhage and is likely to aid growth in market share. While management did not share the number, we believe that CLGT’s direct reach now equals or exceeds 2m outlets, making it the third company apart from HUVR (~3m outlets) and more recently Britannia (~2.1m outlets) to attain that figure.

- **Adspends and promotion spends increased steeply by 20% in 2QFY20** after the arrival of the new MD in Aug'19 (+250bp YoY as a percentage of sales in 2QFY20). The company re-launched Colgate Dental Cream, Colgate Max Fresh with Cooling Crystals, and there has been a lot of communication on the mother brand of late. 'Saver packs' are now a year-round phenomenon rather than occasional earlier. Even INR10 toothpastes come with a brush now.
- **Revival in both premium and mass end (Colgate Cibaca)** augurs well for CLGT, in our view. The premium segment of the market was hurt amidst sharp growth in the salience of the natural segment, but this has changed over the past few months. From 8% of the oral care segment, the premium segment had slipped to 3-4% but is moving back to mid-to-high single-digits (at ~6% now). Similarly, growth at Colgate Cibaca – the company's value product – is recovering. Market share for CLGT is higher in these two segments compared to naturals.

Clearly articulated strategy on volume growth, market share expansion

- After achieving some stability in market share, the new MD, Mr. Ram Raghavan's aim is to expand it further – even if it is at the cost of near-term profitability.
- While we believe that oral care category volume growth on a steady state basis will be in single digits, CLGT has the potential to claw back some of the market share that it had lost over the past four years as a result of this renewed focus and also the aforementioned factors.
- Revival in premiumization bodes well for realization growth, which was hurt over the past 3-4 years partly on account of the surprising decline in the salience of the premium segment amidst the onslaught of herbal. Absence of significant downtrading even in the slowdown also augurs well for realization growth.

Volume growth recovery to be gradual

- Demand has neither revived nor slipped in recent months compared to 3-4 months ago.
- According to management, the expected good Rabi sowing (on account of above-normal monsoon) may not materially alter the demand scenario in rural India for the FMCG sector. At the most, it expects rural growth – which had slipped below urban growth over the past two quarters – to come at par but not surpass urban growth, at least in the next few quarters. This is in contrast to the scenario three quarters ago when rural growth was well above urban (1.3x urban growth) and driving overall growth for the sector.
- Oral care usually recovers with a lag after sector recovery. Management expects mid-single-digit volume growth for the full year. We assume 5.5% volume growth for FY20.

Corporate tax cut benefits yet to be passed on

- Management has not yet passed on the benefit of corporate tax cuts either in the form of price reductions or adspends. In our view, CLGT is waiting for some revival in demand before going the whole hog on adspend/promotion.

- Notably, CLGT was expected to pay taxes at a rate of ~33-34% for FY20 and FY21 before the announcement of the corporate tax cut by the government. Thus, corporate tax cuts will add INR850-1,150m to its profits.
- As mentioned in our [note](#) released after the announcement of the corporate tax cut, we need to assess the second-order effects of this measure. This includes the impact on (1) relative basis (v/s peers) in categories where the company operates and (2) absolute profit and absolute savings v/s peers. In our view, CLGT is well placed on both these fronts, given that Dabur and Patanjali will not see any material gains from the corporate tax cuts. CLGT can spend a significant part of INR850-1,150m incremental PAT by way of promotions/price-offs in an attempt to gain market share. Two points are important here: **(a) Gain further share or lead to further bleeding of peers:** None of its competitors would have such windfall gains, and if they choose to match CLGT's efforts on promotions and price-offs, they would end up bleeding further. **(b) Utilize/institutionalize multi-year benefit over peers:** Importantly, the corporate tax cuts offer multi-year benefits to CLGT, providing it with incremental benefit every year until competitors scale up well.

No material capex until end-2022

- CLGT cited it does not require significant incremental capex until Dec'22. This means that capex will be low until end-FY23.
- As mentioned in our recent [note](#) (where we looked at the similarities between CLGT and other MNCs), CLGT had created significant capacity over FY14-17 before the onslaught of herbal players, which delayed capacity utilization pick-up. Even if volumes for Colgate were to recover to high-single-digits (assuming some market share recovery) from low-to-mid single-digits, PAT growth will be much higher than EBITDA/revenue growth – as was witnessed in Nestle's case recently when it finally got the strategy right and was able to reap the benefits of massive capacity expansion earlier.


Comments on competition

- Management believes that Patanjali has not been gaining share recently.
- Dabur has started doing well in south and west India (traditionally weak geographies for that company) with Dabur Red.
- Lever Ayush has not made any material dent in oral care even in south India.

Non-oral care growth


- While the focus now is on reviving growth in oral care, management is clear that non-oral care will play an important part in driving incremental sales growth over the medium-to-long term. CLGT already has over six million outlets (direct reach of two million, in our view) and once it sets the house back in order in terms of oral care, the company will be aggressive given its ability to piggyback on the existing distribution reach. In our view, CLGT will strategize well to not get into the mass market soaps/detergents businesses.
- Non-oral care is only ~2-3% of sales in India compared to half of global sales for the parent. According to management, while oral care will continue to be by far the largest chunk of sales in India, non-oral care could be a double-digit sales contributor over the next 10 years.

Exhibit 1: While management has not shared latest figures toothpaste market share has been stable of late...




Source: Company, MOSL

Exhibit 2:and market share has expanded in toothbrushes




Source: Company, MOSL

Exhibit 3: Ad spends rose sharply YoY in 2QFY19




Source: Company, MOSL

Exhibit 4: Ad spends as % of sales have been increasing over the past three quarters




Source: Company, MOSL

Exhibit 5: CLGT's toothpaste volume growth expected to be in mid-single-digits in FY20



Source: Company, MOSL

Exhibit 6: Over FY14-17, CLGT incurred significantly higher capex as % of sales than other consumer companies...



Source: Company, MOSL

Exhibit 7: ...thus, capex until FY23 is expected to be low




Exhibit 8: Higher capex over FY14-17 and weak earnings led to higher depreciation as % of EBITDA




Exhibit 9: Expect muted sales growth in FY20 before potentially strong recovery in FY21




Exhibit 10: Expect flat EBITDA in FY20 because of higher adspends before growth in FY21




Exhibit 11: Expect EBITDA margin to expand 60bp over FY19-21




Exhibit 12: Expect PAT growth to be higher than EBITDA growth in FY20 and FY21






Exhibit 13: Colgate Palmolive P/E (x)



Source: Company, MOSL

Exhibit 14: Consumer sector P/E (x)



Source: Company, MOSL

Financials and Valuations

Income Statement							(INR M)
Y/E March	2015	2016	2017	2018	2019	2020E	2021E
Net Sales	39,887	38,682	39,818	41,880	44,624	47,265	53,804
Change (%)	11.0	-3.0	2.9	5.2	6.6	5.9	13.8
COGS	14,677	14,763	14,763	14,887	15,586	16,495	18,584
Gross Profit	25,210	23,919	25,055	26,992	29,039	30,770	35,220
Gross Margin (%)	63.2	61.8	62.9	64.5	65.1	65.1	65.5
Operating expenses	16,920	14,534	15,619	15,855	16,678	18,328	19,997
EBITDA	8,290	9,385	9,435	11,137	12,361	12,442	15,223
Change (%)	22.2	13.2	0.5	18.0	11.0	0.7	22.4
Margin (%)	20.8	24.3	23.7	26.6	27.7	26.3	28.3
Depreciation	750	1,114	1,332	1,565	1,592	1,748	1,849
Int. and Fin. Charges	0	0	0	0	25	80	80
Financial Other Income	264	395	411	375	377	328	332
Profit before Taxes	7,804	8,666	8,514	9,947	11,120	10,942	13,626
Change (%)	17.6	11.1	-1.8	16.8	11.8	-1.6	24.5
Margin (%)	19.6	22.4	21.4	23.8	24.9	23.2	25.3
Tax	2,009	2,541	2,740	3,022	3,717	2,754	3,429
Tax Rate (%)	28.4	29.3	32.2	31.1	33.0	25.2	25.2
Adjusted PAT	5,590	6,125	5,774	6,850	7,451	8,188	10,196
Change (%)	13.9	9.6	-5.7	18.6	8.8	9.9	24.5
Margin (%)	14.0	15.8	14.5	16.4	16.7	17.3	19.0
Non-rec. (Exp)/Income	0	-313	0	-117	305	0	0
Reported PAT	5,590	5,812	5,774	6,734	7,756	8,188	10,196
Balance Sheet							(INR M)
Y/E March	2015	2016	2017	2018	2019	2020E	2021E
Share Capital	272	272	272	272	272	272	272
Reserves	7,431	10,038	12,466	14,974	14,196	13,550	12,368
Net Worth	7,703	10,310	12,738	15,246	14,468	13,822	12,640
Loans	0	0	0	0	777	777	777
Deferred Liability	26	97	275	355	309	309	309
Capital Employed	7,729	10,407	13,013	15,601	15,553	14,908	13,725
Gross Block	12,829	14,866	17,188	19,077	21,077	22,618	23,618
Less: Accum. Deprn.	-5,013	-4,785	-6,107	-7,617	-9,169	-10,916	-12,766
Net Fixed Assets	7,816	10,081	11,081	11,459	11,909	11,702	10,852
Capital WIP	1,412	784	1,666	1,586	1,987	1,987	1,987
Investments	371	312	312	312	312	312	312
Current	371	0	0	0	0	0	0
Non-current	0	312	312	312	312	312	312
Curr. Assets, L&A	7,420	8,852	10,048	12,282	12,058	13,078	13,020
Inventory	2,522	2,915	2,926	2,267	2,486	2,636	2,971
Account Receivables	696	1,015	1,299	2,010	2,098	2,315	2,343
Cash & Bank	2,545	2,887	2,943	4,562	3,994	4,534	3,994
Others	1,657	2,035	2,880	3,443	3,481	3,593	3,713
Curr. Liab. and Prov.	9,290	9,622	10,094	10,037	10,712	12,170	12,446
Account Payables	5,144	5,519	5,975	6,203	6,132	7,534	7,703
Other Liabilities	2,874	3,438	3,356	3,040	3,757	3,772	3,836
Provisions	1,272	664	763	794	823	864	907
Net Current Assets	-1,870	-770	-46	2,245	1,346	908	575
Application of Funds	7,729	10,407	13,013	15,601	15,553	14,908	13,725

E: MOFSL Estimates

Financials and Valuations

Ratios

Y/E March	2015	2016	2017	2018	2019	2020E	2021E
Basic (INR)							
EPS	20.6	22.5	21.2	25.2	27.4	30.1	37.5
Cash EPS	23.3	26.6	26.1	30.9	33.2	36.5	44.3
BV/Share	28.3	37.9	46.8	56.1	53.2	50.8	46.5
DPS	12.5	11.0	11.0	24.0	23.0	26.2	33.7
Payout %	60.6	48.8	51.7	95.3	84.0	87.0	90.0
Valuation (x)							
P/E	72.4	66.1	70.1	59.1	54.3	49.4	39.7
Cash P/E	63.8	55.9	57.0	48.1	44.8	40.7	33.6
EV/Sales	10.1	10.4	10.1	9.5	9.0	8.5	7.5
EV/EBITDA	48.5	42.8	42.6	35.9	32.5	32.2	26.4
P/BV	52.5	39.3	31.8	26.6	28.0	29.3	32.0
Dividend Yield (%)	0.8	0.7	0.7	1.6	1.5	1.8	2.3
Return Ratios (%)							
RoE	81.6	68.0	50.1	49.0	50.1	57.9	77.1
RoCE	82.5	67.5	49.3	47.9	47.9	54.2	71.6
RoIC	236.5	119.0	75.7	76.5	78.4	92.3	129.1
Working Capital Ratios							
Debtor (Days)	6	9	11	17	17	18	16
Asset Turnover (x)	6.7	4.2	3.6	3.1	3.4	3.7	4.7
Leverage Ratio							
Debt/Equity (x)	0.0	0.0	0.0	0.0	0.1	0.1	0.1

Cash Flow Statement

Y/E March	2015	2016	2017	2018	2019	2020E	2021E
(INR M)							
OP/(loss) before Tax	7,804	8,666	8,514	9,947	11,121	10,942	13,626
Depreciation	750	1,114	1,332	1,565	1,592	1,748	1,849
Int./Div. Received	97	-264	34	81	85	-328	-332
Interest Paid	-264	-261	-297	-290	-317	80	80
Direct Taxes Paid	-2,055	-2,524	-3,014	-3,474	-4,144	-2,754	-3,429
(Incr)/Decr in WC	49	156	311	-889	1,494	979	-207
CF from Operations	6,382	6,887	6,880	6,940	9,830	10,667	11,587
(Incr)/Decr in FA	-2,994	-2,713	-3,212	-2,087	-1,042	-1,541	-1,000
Free Cash Flow	3,388	4,175	3,668	4,853	8,788	9,126	10,587
Others	135	12	-205	564	-1,209	1,732	1,735
CF from Invest.	-2,859	-2,631	-3,418	-1,523	-2,251	191	735
Dividend Paid	-3,388	-2,987	-2,717	-2,986	-6,462	-8,833	-11,379
Others	-460	-928	-689	-812	-1,564	-1,484	-1,484
CF from Fin. Activity	-3,848	-3,915	-3,406	-3,798	-8,147	-10,317	-12,863
Incr/Decr of Cash	-325	342	56	1,619	-568	541	-541
Add: Opening Balance	2,870	2,545	2,887	2,943	4,562	3,994	4,534
Closing Balance	2,545	2,887	2,943	4,562	3,994	4,534	3,993

E: MOFSL Estimates

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online-reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months

- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com.CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.